Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)
05 January 2022 - 10:11PM
Edgar (US Regulatory)
FORM 6-K
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
Report
of Foreign Issuer
Pursuant
to Rule 13a-16 or 15d-16 of
the
Securities Exchange Act of 1934
For the
month of January 2022
Commission
File Number: 001-11960
AstraZeneca PLC
1
Francis Crick Avenue
Cambridge
Biomedical Campus
Cambridge
CB2 0AA
United
Kingdom
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form
20-F X Form 40-F __
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(1):
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(7): ______
Indicate
by check mark whether the registrant by furnishing the information
contained in this Form is also thereby furnishing the information
to the Commission pursuant to Rule 12g3-2(b) under the Securities
Exchange Act of 1934.
Yes __
No X
If
“Yes” is marked, indicate below the file number
assigned to the Registrant in connection with Rule 12g3-2(b):
82-_____________
AstraZeneca PLC
INDEX
TO EXHIBITS
1.
Transfer of rights
to Eklira, Duaklir completed
5 January 2022 07:00 GMT
Transfer of global rights
for Eklira and Duaklir to Covis Pharma
completed
AstraZeneca has completed the transfer of its global rights
to Eklira (aclidinium bromide), known
as Tudorza in the US, and Duaklir (aclidinium bromide/formoterol) to Covis
Pharma Group (Covis Pharma).
Financial considerations
Under the terms of the agreement, AstraZeneca received a payment of
$270m from Covis Pharma. AstraZeneca will also receive payments in
respect of certain ongoing development costs related to the
medicines. The income arising from the upfront payment will be
fully offset by a charge for derecognition of the associated
intangible asset and therefore no Other Operating Income will be
recognised in AstraZeneca's financial statements.
Notes
Eklira and Duaklir
Eklira (aclidinium
bromide) and Duaklir (aclidinium bromide/formoterol) are inhaled
respiratory medicines used for the maintenance treatment of chronic
obstructive pulmonary disease. Eklira is a long-acting muscarinic antagonist
(LAMA), which is marketed in the US as Tudorza and in some countries
as Bretaris.
Duaklir is a combination
therapy that contains both a LAMA and a long-acting beta2-agonist
(LABA). It is marketed in some countries
as Brimica.
Both medicines are presented as a dry powder for inhalation and are
delivered via a breath-actuated multi-dose dry powder
inhaler, Genuair (Pressair in the US). AstraZeneca licensed the global rights to both
products from Almirall S.A. in 2014.
AstraZeneca
AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led
biopharmaceutical company that focuses on the discovery,
development, and commercialisation of prescription medicines in
Oncology, Rare Diseases, and BioPharmaceuticals, including
Cardiovascular, Renal & Metabolism, and Respiratory &
Immunology. Based in Cambridge, UK, AstraZeneca operates in over
100 countries and its innovative medicines are used by millions of
patients worldwide. Please visit astrazeneca.com and
follow the Company on Twitter @AstraZeneca.
Contacts
For details on how to contact the Investor Relations Team, please
click here.
For Media contacts, click here.
Adrian Kemp
Company Secretary
AstraZeneca PLC
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized.
Date:
05 January 2022
|
|
By: /s/
Adrian Kemp
|
|
|
Name:
Adrian Kemp
|
|
|
Title:
Company Secretary
|
AstraZeneca (NASDAQ:AZN)
Historical Stock Chart
From Mar 2024 to Apr 2024
AstraZeneca (NASDAQ:AZN)
Historical Stock Chart
From Apr 2023 to Apr 2024
